The revolution of early aggressive treatments for early arthritis (EA) has fuelled the search for better approaches to establishing their cost-utility ratio. The authors aimed to compare the responsiveness of the EQ-5D and the SF-6D in a large prospective cohort of patients with EA. Methods EQ-5D and SF-6D utility measures were assessed in 813 patients with EA over 2 years. Responsiveness was analysed by the standardised response mean (SRM) and effect size between baseline and 6, 12 and 24 months for the entire sample and subgroups by disease evolution (increase or decrease in Disease Activity Score for 28 joints). Bootstrap methods were used to estimate 95% CI. Results The EQ-5D provided larger absolute mean change estimates with greater variance than the SF-6D, whatever the direction of change. At 12 months, the SF-6D was more sensitive to change with improved condition than the EQ-5D: SRM 0.83 (0.82 to 0.84) versus 0.57 (0.56 to 0.58). In contrast, the EQ-5D was more sensitive to change with deteriorated condition than the SF-6D: SRM −0.20 (−0.23 to −0.18) versus −0.11 (−0.14 to −0.08). Results were similar for 6 and 24 months. Conclusions The SF-6D was more responsive than the EQ-5D with improved EA condition. Confi dence in the relative cost-effectiveness of two treatments would be better with the SF-6D because of its smaller variance. The SF-6D provided more conservative cost-effectiveness ratios than the EQ-5D and may be more appropriate for trials of biological treatments for patients with EA.
▶ An additional fi gure is published online only. To view these fi les, please visit the journal online (http://ard.bmj.com/ content/early/recent).
INTRODUCTION
Preference-based measures of health have become important for estimating health states in calculations of quality-adjusted life years (QALYs), an essential component of cost-utility analysis. The EQ-5D 1 and the SF-6D 2 are indirect preferencebased health-related quality of life (HRQoL) instruments that are increasingly being used for an economic evaluation of clinical interventions and health programs. Although the theoretical concept of utility implies that one specifi c health state has one utility score, regardless of how it is measured, different instruments can give different scores. 3 The explosion of drug development for rheumatoid arthritis (RA) and the revolution of early aggressive treatments for the disease have fuelled the search for better approaches to establishing cost-effectiveness in early arthritis (EA), but consensus on the EXTENDED REPORT
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Cécile Gaujoux-Viala, 1, 2 Anne-Christine Rat, 1, 3 Francis Guillemin, 1, 3 René-Marc Flipo, 4 Patrice Fardellone, 5 Pierre Bourgeois, 2 Bruno Fautrel 2 choice of utility instrument is lacking. The choice of instrument may affect the results of future studies on new biological agents and their cost-effectiveness. We need a consensus based on the relative merits of the instruments from evidence on their practicality, reliability, construct validity, discriminant validity and responsiveness, as well as their overall suitability for evaluative purposes. Thus, if the measurement properties of the two instruments are close but the elicited utility levels differ, sensitivity analyses using the two measurements of utility could be appropriate for determining costutility ratios.
Several studies, mainly cross-sectional, have compared EQ-5D and SF-6D scores for patients with RA; 4-7 a common fi nding by the two measures is the presence of small but signifi cant differences between utility estimates. [8] [9] [10] However, few comparisons for EA exist. In a previous study, 11 we demonstrated a systematic disagreement between EQ-5D utility and SF-6D utility for EA, especially for patients with worse clinical outcomes: the utility was systematically lower with the EQ-5D. We have also assessed their construct validity and discrimination capacity. 11 One other important aspect of validity is the ability of a measure to refl ect the change in patients' condition over time. The EQ-5D and the SF-6D can detect some degree of change for patients with RA. [12] [13] [14] [15] In two studies of North American populations, the SF-6D appeared more responsive to health improvement in patients with RA than was the EQ-5D. 13 14 However, other results have been confl icting. In patients with different rheumatological conditions (51% RA), the EQ-5D was more responsive to improvement than was the SF-6D. 15 Harrison et al 16 examined the responsiveness of the EQ-5D and the SF-6D in cohorts of patients with early infl ammatory disease or established RA. The SF-6D did not respond well to deteriorated conditions in patients with established severe RA, and its use for patients with severe progressive disease may be inappropriate. In EA, data were limited. Only data on very early infl ammatory arthritis (4-11 weeks' duration, n=182) included in the Steroids in Very Early Arthritis randomised controlled trial (RCT) of intramuscular steroid treatment versus placebo were available. 17 Furthermore, the authors did not differentiate patients by disease activity, functional ability or disease evolution. 16 A recent review of the use of generic utility measures for RA recommended more head-to-head comparisons of the measures in longitudinal studies across the spectrum of RA disease severity. 18 We aimed to compare the responsiveness of the EQ-5D and the SF-6D in a large group of patients with EA followed over 2 years.
PATIENTS AND METHODS Patients
Between December 2002 and March 2005, 813 patients with EA from 14 French regional centres were included in the Étude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort. 19 Inclusion criteria were as follows: age of 18-70 years, more than two swollen joints for >6 weeks and <6 months, suspected or confi rmed diagnosis of RA and not taking disease-modifying anti-rheumatic drugs or steroids (except if <2 weeks). Patients were followed every 6 months during the fi rst 2 years. At baseline and on each visit, data on clinical and biological variables, including data for the Disease Activity Score for 28 joints (DAS28), a composite index of disease activity, were collected. 20 Furthermore, on each visit, patients completed self-administered patient-reported outcome measures, including a functional ability questionnaire, the Health Assessment Questionnaire (HAQ) 21 and HRQoL questionnaires, the EQ-5D and the 36-Item Short Form Health Survey. 22 The protocol for the ESPOIR cohort study was approved by the ethics committee of Montpellier, France. All patients gave their signed informed consent before inclusion in the study.
Utility measurement
Assessment of utility involves assigning a numeric value from 0 to 1 for health states, where 0 indicates death and 1 indicates a state of perfect health. The values refl ect the preference for a health state in a situation of choice, which includes uncertainty or sacrifi ce (eg, life years). Methods such as standard gamble and time tradeoff (TTO) may be used to measure health states directly, but they are less suitable for clinical research and less widely used for feasibility reasons. Instead, indirect utility assessment techniques, namely the EQ-5D and the SF-6D, have been developed. Indirect health utility assessments involve population-assigned weights to calculate utility scores for particular health states from multidomain health status questionnaires completed by patients 23 (table 1) .
Statistical analysis
EQ-5D and SF-6D utility scores were calculated using the scoring algorithms developed by Dolan 1 and Brazier et al, 2 respectively, using UK population weights. Descriptive statistics (mean±standard deviation, median IQR, minimum and maximum) and distributions of the changes in EQ-5D and SF-6D utility scores were computed. Ceiling and fl oor effects were compared and considered present if >15% of the respondents had the highest or lowest possible score. 25 To investigate whether the changes in the EQ-5D and the SF-6D are valid measures of change in EA health status, we used Spearman's product-moment correlation to compare the change scores for the two instruments with those for external measures of health (the HAQ and DAS28) from baseline to 6, 12 or 24 months. (5) Pain (6) Mental health (5) Vitality (5) *The SF-6D can also be calculated using the 12-Item Short Form Health Survey. 24 TTO, time tradeoff; SF-36, 36-Item Short Form Health Survey. 
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Responsiveness
The responsiveness of the EQ-5D and the SF-6D was assessed by use of effect size (ES) and the standardised response mean (SRM) at 12 months for the entire sample and for subgroups categorised by disease activity at baseline (DAS28 ≤3.2, 3.2-5.1 and >5.1), by functional ability at baseline (HAQ ≤1, 1-2 and >2) and by disease activity evolution (DAS28 change <0 (disease activity improvement) or >0 (disease activity deterioration)). Both ES and SRM provide a ratio of signal (mean change) to noise (SD). ES is calculated as the ratio of the mean change between baseline and follow-up assessment to the SD of the group at baseline. 26 SRM is calculated as the ratio of the mean change between baseline and follow-up assessment to the SD of the mean change. 27 By convention, an ES of <0.2 is usually considered trivial, an ES of 0.2-0.5 is considered small, an ES of 0.5-0.8 is considered moderate, an ES of 0.8-1.2 is considered important and an ES of >1.2 is considered very important. 28 SRM values of >0.8 are considered large. Sensitivity to change in the HAQ was calculated as a benchmark. Because the standard errors of distribution-based approaches are not defi ned, we used bootstrap methods to estimate the 95% confi dence intervals for the SRM and ES values to allow a comparison between the SF-6D and the EQ-5D. 29 In assessing the robustness of the main conclusions, sensitivity analyses involved assessing responsiveness (1) in patients with active disease and those with a high probability of RA-candidates for new treatments for which cost-effectiveness studies are necessary (ie, patients fulfi lling the new American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) criteria for RA 30 and with at least moderate disease activity (DAS28 >3.2)), and (2) in patients at 6 and 24 months to confi rm sensitivity to change over time (using ES and SRM between baseline and month 6, and between baseline and month 24, respectively).
All analyses involved the use of SAS v9.1 (SAS Institute, Cary, North Carolina, USA). p<0.05 was considered statistically signifi cant. Table 2 shows the demographic and clinical characteristics of the 813 patients in the ESPOIR cohort at inclusion. In total, 641 (78.8%) patients fulfi lled the new ACR-EULAR criteria for RA. The results are for the patients for whom data were available. At 2 years, 692 patients were still being followed up, and all demographic characteristics were similar to those of the initial population.
RESULTS

Characteristics of the population
Utility scores
The distribution of utility scores was bimodal for the EQ-5D and near normal for the SF-6D (online supplementary fi gure S1). At baseline, the mean utility score for the EQ-5D was 0.518±0.306 (median 0.656 (IQR 0.255-0.725)) and for the SF-6D was 0.582±0.114 (median 0.580 (IQR 0.519-0.646)). The EQ-5D generated a minimum value of −0.594 and a maximum value of 1.0, with 11.8% of patients in health states considered worse than dead (<0) and with 1.5% of patients with a corresponding utility score of 1.0. In contrast, the SF-6D generated a minimum value of 0.301 and a maximum value of 0.923. Thus, no significant fl oor or ceiling effect was found at baseline. However, at 6 months, 6% of patients had an EQ-5D utility score of 1.0; this proportion increased at 1 year then remained stable over time at ~12%. The proportion of patients with an SF-6D utility score of 1.0 remained low at between 0.5% and 0.7%.
The distribution of utility changes was near normal for the EQ-5D and the SF-6D (fi gure 1). The correlation of change in the EQ-5D with change in the SF-6D at 12 months was moderate (r=−0.57) (table 3). The correlations of utility change, using the two instruments, with changes in DAS28 and HAQ scores were moderate, similar for the SF-6D and the EQ-5D, and stable over 2 years. The correlations of utility change, using the two instruments, with change in pain at rest were weak. The results were similar at 6 and 24 months (table 3) .
Eleven patients experienced a change in the EQ-5D of more than one unit at 12 months. As expected, these patients had a very severe and active disease at baseline (mean DAS28 6.67±1.25; group.bmj.com on September 19, 2012 -Published by ard.bmj.com Downloaded from mean HAQ 2.10±0.53; mean EQ-5D −0.134±0.128; mean SF-6D 0.458±0.088) and showed great improvement at 12 months (change in DAS28 −4.37±0.96; change in HAQ −1.95±0.58). It should be noted that all of these patients had baseline EQ-5D utilities valued at less than 0 or as worse than dead.
Responsiveness
For the entire sample at 12 months, the SF-6D was more sensitive to change than was the EQ-5D: SRM 0.74 (95% CI 0.73 to 0.75) versus 0.49 (95% CI 0.48 to 0.50). For subgroups categorised by disease activity (DAS28 ≤3.2, 3.2-5.1 and >5.1) or by functional ability (HAQ ≤1, 1-2 and >2) at baseline, the SF-6D was always more responsive than the EQ-5D (table 4) . More patients had improved condition than deteriorated condition (table 5) .
The EQ-5D produced larger absolute mean change estimates with greater variance than did the SF-6D, whatever the direction of change (table 5) .
At 12 months, the SF-6D showed greater sensitivity to change than the EQ-5D with improved condition: SRM 0.83 (0.82 to 0.84) versus 0.57 (0.56 to 0.58). The EQ-5D was more sensitive to change than was the SF-6D for deteriorated condition: SRM −0.20 (−0.23 to −0.18) versus −0.11 (−0.14 to −0.08) (table 5).
For patients with improved condition, the sensitivity to change in the SF-6D was similar to that in the HAQ, whereas for patients with deteriorated condition, the sensitivity to change in the EQ-5D was close to that in the HAQ (table 5) .
The results were similar at 6 and 24 months, except for patients with deteriorated condition at 6 months: the EQ-5D and the SF-6D did not detect deteriorated disease activity (DAS28 mean change 0.48±0.44) and showed a very small gain in utility. The results were similar for patients fulfi lling the new ACR-EULAR criteria for RA and patients with at least moderate disease activity at baseline (data not shown).
DISCUSSION
This study is the fi rst to compare the responsiveness of the EQ-5D and the SF-6D in a large cohort of patients with EA. The responsiveness of the EQ-5D and the SF-6D differed according to the direction of change in EA condition. The SF-6D was more responsive to improved condition, and the EQ-5D was more responsive to deteriorated condition. The high mean change in the EQ-5D relative to the SF-6D has consequences for costeffectiveness analyses.
One of the strengths of our study is its investigation of a large diverse group of patients with EA. The observational ESPOIR cohort aimed to include all patients with EA regardless of disease level, age and sex, and our study implied the performance of the instruments in a real-life setting. The study also included a large number of patients with longitudinal assessment and individual data allowing for the differentiation of patients with improved and deteriorated conditions. Moreover, we could investigate patients with active disease and those with a high probability of RA-candidates for new treatments for which cost-effectiveness studies are necessary.
Our study has some limitations. We did not compare the test-retest reliability of these two instruments. The scoring algorithms used for both instruments were developed from the general population in the UK because no such algorithm was available in France at the time of the study.
However, the use of an algorithm from the same population for the EQ-5D and the SF-6D might result in a more valid comparison. Valuations of profi les (USA, Denmark, Spain and Japan) Table 5 : Mean change and responsiveness of the EQ-5D and the SF-6D according to the evolution of patients' condition at 6, 12 and 24 months 
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group.bmj.com on September 19, 2012 -Published by ard.bmj.com Downloaded from may vary according to how sets of preference weights for health profi les were developed. We chose to use British estimates since a UK study-the PRINCEPS study, which had the largest sample size overall and in the European population-provided the most robust estimates and is widely used in Europeans countries where national references are missing/lacking. Our results were similar to those found for more heterogeneous RA. 14 18 All previous studies have suggested that both measures are generally responsive to changed condition in patients with RA, consistent with our results. 13-15 18 Concerning EA, Harrison et al 16 showed that the SF-6D was more responsive than the EQ-5D for 181 patients included in the Steroids in Very Early Arthritis RCT of intramuscular steroid treatment versus placebo over 1 year: SRM 0.83 versus 0.64. However, the authors did not differentiate patients by disease activity, functional ability or disease evolution. Moreover, they did not provide 95% CI to allow comparisons between the different SRMs.
Several reasons might explain this difference between utility scores, and concerns have been voiced about the ability of the EQ-5D to measure change owing to its bimodal distribution, its three answer modalities and possible ceiling effects within domains. 4 14 15 18 Five-level answer modalities for the EQ-5D have been developed but are not yet widely used. 31 One explanation for the difference in utility scores is that the health descriptive system of the SF-6D does not allow for negative values and thus assigns a 0.296 value to the most severe health state produced by the descriptive system, whereas the EQ-5D score allows for negative scores. 32 33 Second, EQ-5D utility scores are TTO based, tending to result in high values for mild states, whereas SF-6D scores are standard gamble based, tending to result in high values for severe states. 34 35 For the TTO valuation procedure, each state is considered to last 10 years without change, 1 which may explain in part the low valuations given to the most severe health states. The low EQ-5D utility scores for patients with severe disabilities may also be explained by the content of the EQ-5D. Of the fi ve dimensions, four (mobility, self-care, usual activity and pain/discomfort) are likely to be particularly affected in patients with EA. Finally, the scoring algorithm subtracts a value of 0.269 for a score of 3 (ie, severe problems) in at least one dimension.
The SF-6D may be more sensitive (because of its larger descriptive system) than the EQ-5D for patients experiencing mild to moderate health problems. 2 With only three response levels for each dimension, the EQ-5D does not allow for gradations between no problem, moderate problem, and severe problem.
The correlations of utility change, using the two instruments, with change in the DAS28 and HAQ scores were moderate, similar for the SF-6D and the EQ-5D, and stable over 2 years. Moderate correlations suggest that both tools measure a similar underlying construct and show similar longitudinal validity. Utilities measure patients' perspective on their health state using population-assigned weights, while the HAQ assesses patients' report of their functioning and DAS28 only refl ects the activity. Although these two concepts are related, they are not identical.
Responsiveness indices give an indication of whether a measure can detect a true change over noise but does not indicate whether the detected change is meaningful or useful. 36 As an outcome measure in an epidemiological setting, the SF-6D requires a smaller sample size than the EQ-5D to detect improvements in patients whose health is improving. The opposite is true for patients with worsening condition. However, in economic analyses, the approach is different. The larger mean change in patients with improving and deteriorating conditions suggests that an intervention will more likely be considered costeffective if assessed by the EQ-5D rather than by the SF-6D. In cost-utility analysis, the incremental cost of an intervention in a group is divided by its incremental effectiveness in this group, measured by an instrument such as the EQ-5D or the SF-6D. The gain in the EQ-5D will be larger and will provide more favourable incremental cost-utility ratios than the SF-6D. A recent study of RA reported that the change estimated with the EQ-5D resulted in a cost per QALY that was more than 50% lower than the cost per QALY calculated with the SF-6D. 37 However, because the mean effect is only an estimate, the uncertainty around the estimate must be presented. The smaller variance of the SF-6D should result in less uncertainty in estimating the relative costeffectiveness of two treatments.
Our study cannot answer the question of which index score is more valid as a measure of preference-based HRQoL. However, we can provide tentative suggestions, with the caveat that the choice of instrument should be guided by the appropriateness of the tool for its intended use. We have demonstrated three important elements. First, the SF-6D was more responsive than the EQ-5D for improved EA condition. Second, the smaller variance of the SF-6D should result in less uncertainty in estimating the relative cost-effectiveness of two treatments. Third, the SF-6D was more conservative than the EQ-5D, providing more optimistic cost-effectiveness ratios than the SF-6D. Therefore, the SF-6D may be more appropriate for use in RCTs of biological treatments for patients with EA.
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